Literature DB >> 22405656

Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features.

Clemente Garcia-Rizo1, Emilio Fernandez-Egea, Cristina Oliveira, Azucena Justicia, Miguel Bernardo, Brian Kirkpatrick.   

Abstract

Newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis appear to have increases in pro-inflammatory cytokines. Patients characterized by primary, enduring negative symptoms (deficit symptoms) differ from patients without such features with regard to course of illness, treatment response, risk factors and metabolic disturbances. We hypothesized that they would also differ on concentrations of the inflammatory markers interleukin-6 (IL6) and C-reactive protein (CRP). Newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis were categorized into deficit (N=20) and nondeficit (N=42) groups, and were matched on age, gender, body mass index, smoking, cortisol level, socioeconomic status, and the severity of psychotic symptoms. Fasting concentrations of IL6 were significantly higher in deficit (mean [S.D.]) (8.0 pg/ml [12.7]) than nondeficit patients (0.3 pg/ml [1.3]). CRP levels were also significantly higher in the deficit patients (0.3 mg/dl [0.4]) vs. (0.2 mg/dl [0.4]), respectively. In contrast, 2-h glucose concentrations (2HG) in a glucose tolerance test were lower in the deficit than the nondeficit group. Our results show a double dissociation with regard to glucose intolerance and inflammation: the deficit group has greater inflammation, but less severe glucose intolerance. These results provide further evidence for the validity of the deficit/nondeficit categorization.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22405656      PMCID: PMC3374916          DOI: 10.1016/j.psychres.2011.08.014

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  50 in total

1.  Interleukin-6: the endocrine cytokine.

Authors:  D A Papanicolaou; A N Vgontzas
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

2.  Three dimensions of clinical symptoms in elderly patients with schizophrenia: prediction of six-year cognitive and functional status.

Authors:  Eran Chemerinski; Abraham Reichenberg; Brian Kirkpatrick; Christopher R Bowie; Philip D Harvey
Journal:  Schizophr Res       Date:  2006-04-19       Impact factor: 4.939

3.  Summer birth and the deficit syndrome of schizophrenia.

Authors:  B Kirkpatrick; R Ram; X F Amador; R W Buchanan; T McGlashan; M Tohen; E Bromet
Journal:  Am J Psychiatry       Date:  1998-09       Impact factor: 18.112

4.  The course of cognitive functioning in first episode psychosis: changes over time and impact on outcome.

Authors:  Jean Addington; Huma Saeedi; Donald Addington
Journal:  Schizophr Res       Date:  2005-10-01       Impact factor: 4.939

5.  The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms.

Authors:  M J Schwarz; N Müller; M Riedel; M Ackenheil
Journal:  Med Hypotheses       Date:  2001-04       Impact factor: 1.538

Review 6.  Seasonality of births in schizophrenia and bipolar disorder: a review of the literature.

Authors:  E F Torrey; J Miller; R Rawlings; R H Yolken
Journal:  Schizophr Res       Date:  1997-11-07       Impact factor: 4.939

7.  Double dissociation of N1 and P3 abnormalities in deficit and nondeficit schizophrenia.

Authors:  Armida Mucci; Silvana Galderisi; Brian Kirkpatrick; Paola Bucci; Umberto Volpe; Eleonora Merlotti; Fausto Centanaro; Francesco Catapano; Mario Maj
Journal:  Schizophr Res       Date:  2007-03-23       Impact factor: 4.939

8.  Suspiciousness and alcohol use disorders in schizophrenia.

Authors:  Erick Messias; O Joseph Bienvenu
Journal:  J Nerv Ment Dis       Date:  2003-06       Impact factor: 2.254

9.  The deficit syndrome in the DSM-IV Field Trial. Part II. Depressive episodes and persecutory beliefs.

Authors:  B Kirkpatrick; X F Amador; S A Yale; J R Bustillo; R W Buchanan; M Tohen
Journal:  Schizophr Res       Date:  1996-05       Impact factor: 4.939

10.  Summer birth and deficit schizophrenia: Cantabria, Spain.

Authors:  Brian Kirkpatrick; Sara Herrera Castanedo; Jose L Vazquez-Barquero
Journal:  J Nerv Ment Dis       Date:  2002-08       Impact factor: 2.254

View more
  29 in total

1.  Are Negative Symptoms Dimensional or Categorical? Detection and Validation of Deficit Schizophrenia With Taxometric and Latent Variable Mixture Models.

Authors:  Anthony O Ahmed; Gregory P Strauss; Robert W Buchanan; Brian Kirkpatrick; William T Carpenter
Journal:  Schizophr Bull       Date:  2014-11-14       Impact factor: 9.306

Review 2.  Inflammation and schizophrenia.

Authors:  Brian Kirkpatrick; Brian J Miller
Journal:  Schizophr Bull       Date:  2013-09-26       Impact factor: 9.306

3.  An Early Developmental Marker of Deficit versus Nondeficit Schizophrenia.

Authors:  Brian Kirkpatrick; Özlem Gürbüz Oflezer; Mehtap Delice Arslan; Gary Hack; Emilio Fernandez-Egea
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

4.  TNF-α and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia.

Authors:  David R Goldsmith; Ebrahim Haroon; Andrew H Miller; Gregory P Strauss; Peter F Buckley; Brian J Miller
Journal:  Schizophr Res       Date:  2018-02-28       Impact factor: 4.939

5.  Peripheral endocannabinoid system dysregulation in first-episode psychosis.

Authors:  Miquel Bioque; Borja García-Bueno; Karina S Macdowell; Ana Meseguer; Pilar A Saiz; Mara Parellada; Ana Gonzalez-Pinto; Roberto Rodriguez-Jimenez; Antonio Lobo; Juan C Leza; Miguel Bernardo
Journal:  Neuropsychopharmacology       Date:  2013-07-04       Impact factor: 7.853

Review 6.  Primary, Enduring Negative Symptoms: An Update on Research.

Authors:  Brian Kirkpatrick; Armida Mucci; Silvana Galderisi
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

7.  Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms.

Authors:  Deanna L Kelly; Kelli M Sullivan; Joseph P McEvoy; Robert P McMahon; Heidi J Wehring; James M Gold; Fang Liu; Dale Warfel; Gopal Vyas; Charles M Richardson; Bernard A Fischer; William R Keller; Maju Mathew Koola; Stephanie M Feldman; Jessica C Russ; Richard S E Keefe; Jennifer Osing; Leeka Hubzin; Sharon August; Trina M Walker; Robert W Buchanan
Journal:  J Clin Psychopharmacol       Date:  2015-08       Impact factor: 3.153

8.  The risk of diabetes in deficit schizophrenia.

Authors:  William R Keller; Carol Vidal; Eric S Park; Gregory P Strauss; Bernard A Fischer
Journal:  Clin Schizophr Relat Psychoses       Date:  2014-01

Review 9.  The role of cortisol in first episode of psychosis: a systematic review.

Authors:  Evangelos Karanikas; Diomidis Antoniadis; George D Garyfallos
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

10.  Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups.

Authors:  Jamie Joseph; Colin Depp; Averria Sirkin Martin; Rebecca E Daly; Danielle K Glorioso; Barton W Palmer; Dilip V Jeste
Journal:  Schizophr Res       Date:  2015-09-02       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.